Mumbai, June 8 -- Panacea Biotec announced the launch of the DENSTAR project which will work to advance the licensure of the dengue vaccine DengiAll(R) in sub-Saharan Africa (sSA) and to facilitate its broader global use. The four-year initiative is funded under the Global Health European & Developing Countries Clinical Trials Partnership 3 Joint Undertaking (GH EDCTP3 JU), supported by the European Union and aligns with the EDCTP3 mission to combat Neglected Tropical Diseases (NTDs), including dengue fever, and seeks to reduce the disease burden across Africa.

Published by HT Digital Content Services with permission from Capital Market....